Literature DB >> 33803472

Plumbagin, a Biomolecule with (Anti)Osteoclastic Properties.

Sevinj Sultanli1, Soni Ghumnani2, Richa Ashma2, Katharina F Kubatzky1.   

Abstract

Plumbagin is a plant-derived naphthoquinone that is widely used in traditional Asian medicine due to its anti-inflammatory and anti-microbial properties. Additionally, plumbagin is cytotoxic for cancer cells due to its ability to trigger reactive oxygen species (ROS) formation and subsequent apoptosis. Since it was reported that plumbagin may inhibit the differentiation of bone resorbing osteoclasts in cancer-related models, we wanted to elucidate whether plumbagin interferes with cytokine-induced osteoclastogenesis. Using C57BL/6 mice, we unexpectedly found that plumbagin treatment enhanced osteoclast formation and that this effect was most pronounced when cells were pre-treated for 24 h with plumbagin before subsequent M-CSF/RANKL stimulation. Plumbagin caused a fast induction of NFATc1 signalling and mTOR-dependent activation of p70S6 kinase which resulted in the initiation of protein translation. In line with this finding, we observed an increase in RANK surface expression after Plumbagin stimulation that enhanced the responsiveness for subsequent RANKL treatment. However, in Balb/c mice and Balb/c-derived RAW264.7 macrophages, these findings could not be corroborated and osteoclastogenesis was inhibited. Our results suggest that the effects of plumbagin depend on the model system used and can therefore either trigger or inhibit osteoclast formation.

Entities:  

Keywords:  ROS; mTOR; osteoclast; phytotherapy; plumbagin; translation

Mesh:

Substances:

Year:  2021        PMID: 33803472      PMCID: PMC7967158          DOI: 10.3390/ijms22052779

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  43 in total

Review 1.  Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy.

Authors:  Thomas Efferth; Egon Koch
Journal:  Curr Drug Targets       Date:  2011-01       Impact factor: 3.465

Review 2.  Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems.

Authors:  Hiroshi Takayanagi
Journal:  Nat Rev Immunol       Date:  2007-04       Impact factor: 53.106

3.  The alarmin S100A9 hampers osteoclast differentiation from human circulating precursors by reducing the expression of RANK.

Authors:  Irene Di Ceglie; Arjen B Blom; Robab Davar; Colin Logie; Joost H A Martens; Ehsan Habibi; Lisa-Marie Böttcher; Johannes Roth; Thomas Vogl; Carl S Goodyear; Peter M van der Kraan; Peter L van Lent; Martijn H van den Bosch
Journal:  FASEB J       Date:  2019-06-14       Impact factor: 5.191

4.  Influence of Pasteurella multocida Toxin on the differentiation of dendritic cells into osteoclasts.

Authors:  Sushmita Chakraborty; Bianca Kloos; Nina Roetz; Silke Schmidt; Tatjana Eigenbrod; Shigeki Kamitani; Katharina F Kubatzky
Journal:  Immunobiology       Date:  2017-09-12       Impact factor: 3.144

5.  Continuous application of compressive force induces fusion of osteoclast-like RAW264.7 cells via upregulation of RANK and downregulation of LGR4.

Authors:  Rieko Matsuike; Hideki Tanaka; Kumiko Nakai; Mai Kanda; Maki Nagasaki; Fumiko Murakami; Chika Shibata; Kotoe Mayahara; Akira Nakajima; Natsuko Tanabe; Takayuki Kawato; Masao Maeno; Noriyoshi Shimizu
Journal:  Life Sci       Date:  2018-03-20       Impact factor: 5.037

6.  Alternative NF-κB Regulates RANKL-Induced Osteoclast Differentiation and Mitochondrial Biogenesis via Independent Mechanisms.

Authors:  Rong Zeng; Roberta Faccio; Deborah V Novack
Journal:  J Bone Miner Res       Date:  2015-08-06       Impact factor: 6.741

7.  Reduced miR-144-3p expression in serum and bone mediates osteoporosis pathogenesis by targeting RANK.

Authors:  Chunqing Wang; Hanliang He; Liang Wang; Yu Jiang; Youjia Xu
Journal:  Biochem Cell Biol       Date:  2018-01-15       Impact factor: 3.626

8.  Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt.

Authors:  Kerstin Tiedemann; Damien Le Nihouannen; Jenna E Fong; Osama Hussein; Jake E Barralet; Svetlana V Komarova
Journal:  Front Cell Dev Biol       Date:  2017-05-18

Review 9.  Bone Metastasis: Current State of Play.

Authors:  Anthony Turpin; Martine Duterque-Coquillaud; Marie-Hélène Vieillard
Journal:  Transl Oncol       Date:  2019-12-23       Impact factor: 4.243

Review 10.  Plant Secondary Metabolites as Anticancer Agents: Successes in Clinical Trials and Therapeutic Application.

Authors:  Ana M L Seca; Diana C G A Pinto
Journal:  Int J Mol Sci       Date:  2018-01-16       Impact factor: 5.923

View more
  3 in total

1.  Molecular Dynamic Simulation Analysis on the Inclusion Complexation of Plumbagin with β-Cyclodextrin Derivatives in Aqueous Solution.

Authors:  Kulpavee Jitapunkul; Pisanu Toochinda; Luckhana Lawtrakul
Journal:  Molecules       Date:  2021-11-10       Impact factor: 4.411

2.  Pharmacokinetics of Herb-Drug Interactions of Plumbagin and Tazemetostat in Rats by UPLC-MS/MS.

Authors:  Heng Li; Ying-Jie Wang; Xiao-Nan Geng; Yao-Ren Kang; Yi-Lin Wang; Xiang-Jun Qiu
Journal:  Drug Des Devel Ther       Date:  2022-09-29       Impact factor: 4.319

3.  Plumbagin, a Natural Product with Potent Anticancer Activities, Binds to and Inhibits Dihydroorotase, a Key Enzyme in Pyrimidine Biosynthesis.

Authors:  Hong-Hsiang Guan; Yen-Hua Huang; En-Shyh Lin; Chun-Jung Chen; Cheng-Yang Huang
Journal:  Int J Mol Sci       Date:  2021-06-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.